Chemotherapy remains a cornerstone of lung cancer treatment, but its usefulness is often constrained by two stubborn problems: tumors develop resistance to the drugs, and the systemic toxicities that accompany treatment limit how much patients can tolerate. A newly published review in Discover Oncology examines whether sonodynamic therapy (SDT), an investigational approach that uses ultrasound to trigger the production of reactive oxygen species (ROS) inside tumor tissue, could help overcome these limitations. The review, authored by Lin Wei, Min Zhou, and Renfu Lu, critically evaluates the mechanistic rationale and the lung cancer-specific preclinical evidence for SDT and its combined form, chemo-sonodynamic therapy (CSDT), while clearly separating what has been demonstrated in lung cancer models from what has been extrapolated from other tumor types.

In CSDT, ultrasound-triggered reactive oxygen species are used to injure tumor cells and potentiate drug activity. The review emphasizes that this is an investigational strategy, not an established clinical option, and that the available lung cancer-specific evidence comprises 20 primary studies.

Those 20 studies span a range of experimental directions. Early work involved chlorin e6 and sinoporphyrin sodium experiments. Later studies explored nanocarrier-based drug delivery, hypoxia modulation, resistance reversal, orthotopic pulmonary delivery, and more recent SDT-immunotherapy platforms. The review notes that this body of work is dominated by non-small-cell lung cancer, ectopic tumor models, short-term endpoints, and incompletely reported acoustic exposures. Only one study used a small-cell lung cancer model, and clinical efficacy and safety in patients have not yet been established.

The review also examines the practical challenges of delivering ultrasound to lung tumors. Pulmonary acoustic barriers, realistic transthoracic and endoscopic delivery routes, and ultrasound dosimetry are all identified as key considerations. Nanocarrier manufacturability and safety are additional hurdles that must be addressed before any clinical translation can be justified.

One emerging but still preclinical area is the intersection of SDT with immune checkpoint blockade. The authors frame their analysis as an evidence-graded, delivery-oriented framework designed to identify the specific experiments needed before clinical translation can be justified. They separate mechanistic rationale from lung cancer-specific preclinical evidence and from evidence extrapolated from other tumor types, making clear that the current state of the field does not yet support claims of clinical benefit.

Subject of Research: A review of preclinical evidence on combining chemotherapy with ultrasound-triggered sonodynamic therapy for lung cancer treatment.

Article Title: Integrating chemotherapy and sonodynamic therapy for lung cancer: a review

Article References: Wei, L., Zhou, M., & Lu, R. (2026). Integrating chemotherapy and sonodynamic therapy for lung cancer: a review. Discover Oncology. https://doi.org/10.1007/s12672-026-06258-5

Image Credits: AI Generated

DOI: 10.1007/s12672-026-06258-5

Keywords: lung cancer, sonodynamic therapy, chemotherapy, chemo-sonodynamic therapy, reactive oxygen species, nanocarriers, ultrasound dosimetry, hypoxia modulation, drug resistance, immunotherapy, preclinical research, Integrating